Dun & Bradstreet [DNB] vs CME [CME] Detailed Stock Comparison
Dun & Bradstreet
NYSE
Loading...
CME
NASDAQ
Loading...
TLDR: Quick Comparison Summary
Based on 20 vital metrics comparison: Dun & Bradstreet wins in 6 metrics, CME wins in 13 metrics, with 0 ties. CME appears stronger overall.
View Metrics Details
Vital Metrics Comparison
| Metric | Dun & Bradstreet | CME | Better |
|---|---|---|---|
| P/E Ratio (TTM) | -130.14 | 26.46 | Dun & Bradstreet |
| Price-to-Book Ratio | 1.23 | 3.54 | Dun & Bradstreet |
| Debt-to-Equity Ratio | 106.76 | 13.60 | CME |
| PEG Ratio | -1.30 | 1.69 | Dun & Bradstreet |
| EV/EBITDA | 11.99 | 22.03 | Dun & Bradstreet |
| Profit Margin (TTM) | -1.60% | 58.59% | CME |
| Operating Margin (TTM) | 3.54% | 66.87% | CME |
| EBITDA Margin (TTM) | 3.54% | 66.87% | CME |
| Return on Equity | -1.03% | 13.61% | CME |
| Return on Assets (TTM) | 1.60% | 1.74% | CME |
| Free Cash Flow (TTM) | $223.00M | $3.60B | CME |
| Dividend Yield | N/A | 4.30% | N/A |
| 1-Year Return | -24.90% | 30.17% | CME |
| Price-to-Sales Ratio (TTM) | 1.69 | 15.31 | Dun & Bradstreet |
| Enterprise Value | $7.35B | $100.17B | CME |
| EV/Revenue Ratio | 3.05 | 15.57 | Dun & Bradstreet |
| Gross Profit Margin (TTM) | 58.58% | 86.90% | CME |
| Revenue per Share (TTM) | $6 | $18 | CME |
| Earnings per Share (Diluted) | $-0.09 | $10.33 | CME |
| Beta (Stock Volatility) | 1.12 | 0.46 | CME |
Performance
Key Stats
Valuation
Financials
Short Interest
Dividends
Dun & Bradstreet vs CME Stock Performance Analysis
Loading Price Chart...
Performance Comparison
Short-term Returns
| Stock | 1D | 1W | 1M | 3M | 6M | YTD |
|---|---|---|---|---|---|---|
| Dun & Bradstreet | 0.00% | 0.22% | -0.11% | 1.33% | -1.30% | -26.23% |
| CME | -1.39% | -1.61% | -1.86% | -4.43% | 8.79% | 15.81% |
Long-term Returns
| Stock | 1Y | 3Y | 5Y | 10Y | 15Y | 20Y |
|---|---|---|---|---|---|---|
| Dun & Bradstreet | -24.90% | -37.65% | -63.99% | -66.38% | -66.38% | -66.38% |
| CME | 30.17% | 37.27% | 52.25% | 184.84% | 424.87% | 400.97% |
Performance & Financial Health Analysis: Dun & Bradstreet vs CME
| Metric | DNB | CME |
|---|---|---|
| Market Information | ||
| Market Cap | $4.06B | $98.50B |
| Market Cap Category | Mid cap | Large cap |
| 10 Day Avg. Volume | 3,564,390 | 1,920,550 |
| 90 Day Avg. Volume | 3,004,990 | 2,006,950 |
| Last Close | $9.11 | $269.52 |
| 52 Week Range | $7.78 - $12.94 | $206.44 - $290.79 |
| % from 52W High | -29.63% | -7.31% |
| All-Time High | $29.55 (Nov 02, 2020) | $290.79 (Jun 02, 2025) |
| % from All-Time High | -69.17% | -7.31% |
| Growth Metrics | ||
| Quarterly Revenue Growth | 0.02% | 0.10% |
| Quarterly Earnings Growth | 0.02% | 0.16% |
| Financial Health | ||
| Profit Margin (TTM) | -0.02% | 0.59% |
| Operating Margin (TTM) | 0.04% | 0.67% |
| Return on Equity (TTM) | -0.01% | 0.14% |
| Debt to Equity (MRQ) | 106.76 | 13.60 |
| Cash & Liquidity | ||
| Book Value per Share (MRQ) | $7.41 | $77.13 |
| Cash per Share (MRQ) | $0.64 | $5.82 |
| Operating Cash Flow (TTM) | $454.50M | $4.20B |
| Levered Free Cash Flow (TTM) | $593.36M | $2.92B |
| Dividends | ||
| Last 12-Month Dividend Yield | N/A | 4.30% |
| Last 12-Month Dividend | N/A | $11.85 |
Valuation & Enterprise Metrics Analysis: Dun & Bradstreet vs CME
| Metric | DNB | CME |
|---|---|---|
| Price Ratios | ||
| P/E Ratio (TTM) | -130.14 | 26.46 |
| Forward P/E | 8.21 | 26.36 |
| PEG Ratio | -1.30 | 1.69 |
| Price to Sales (TTM) | 1.69 | 15.31 |
| Price to Book (MRQ) | 1.23 | 3.54 |
| Market Capitalization | ||
| Market Capitalization | $4.06B | $98.50B |
| Enterprise Value | $7.35B | $100.17B |
| Enterprise Value Metrics | ||
| Enterprise to Revenue | 3.05 | 15.57 |
| Enterprise to EBITDA | 11.99 | 22.03 |
| Risk & Other Metrics | ||
| Beta | 1.12 | 0.46 |
| Book Value per Share (MRQ) | $7.41 | $77.13 |
Financial Statements Comparison: Dun & Bradstreet vs CME
Financial Metrics
Loading Financial Charts...
Revenue
EBITDA
Operating Margin
Free Cash Flow
Long Term Debt
Profit Margin
Current Ratio
Operating Cash Flow
Income Statement (MRQ)
| Metric (MRQ) | DNB | CME |
|---|---|---|
| Revenue/Sales | $579.80M | $1.64B |
| Cost of Goods Sold | $227.80M | $206.70M |
| Gross Profit | $352.00M | $1.44B |
| Research & Development | N/A | N/A |
| Operating Income (EBIT) | $38.20M | $1.11B |
| EBITDA | $185.70M | $476.30M |
| Pre-Tax Income | $-14.80M | $1.24B |
| Income Tax | $400,000 | $288.60M |
| Net Income (Profit) | $-14.80M | $956.20M |
Balance Sheet & Liquidity Metrics (MRQ)
| Metric (MRQ) | DNB | CME |
|---|---|---|
| Cash & Equivalents | $241.30M | $1.41B |
| Total Current Assets | $650.40M | $123.45B |
| Total Current Liabilities | $1.05B | $121.42B |
| Long-Term Debt | $3.53B | $3.42B |
| Total Shareholders Equity | $3.31B | $27.03B |
| Retained Earnings | $-855.50M | $4.69B |
| Property, Plant & Equipment | $187.80M | $371.20M |
Cash Flow Statement Comparison (MRQ)
| Metric (MRQ) | DNB | CME |
|---|---|---|
| Operating Cash Flow | $228.10M | $838.30M |
| Capital Expenditures | N/A | $-14.20M |
| Free Cash Flow | $90.20M | $1.10B |
| Debt Repayment | $-67.80M | $-750.00M |
| Common Stock Repurchase | N/A | N/A |
Short Interest & Institutional Ownership Analysis
| Metric | DNB | CME |
|---|---|---|
| Shares Short | 17.88M | 5.42M |
| Short Ratio | 6.53 | 2.53 |
| Short % of Float | 0.05% | 0.02% |
| Average Daily Volume (10 Day) | 3,564,390 | 1,920,550 |
| Average Daily Volume (90 Day) | 3,004,990 | 2,006,950 |
| Shares Outstanding | 441.55M | 359.61M |
| Float Shares | 315.39M | 358.78M |
| % Held by Insiders | 0.09% | 0.00% |
| % Held by Institutions | 0.90% | 0.92% |
Dividend Analysis & Yield Comparison: Dun & Bradstreet vs CME
| Metric | DNB | CME |
|---|---|---|
| Last 12-Month Dividend | N/A | $11.85 |
| Last 12-Month Dividend Yield | N/A | 4.30% |
| 3-Year Avg Annual Dividend | N/A | $10.10 |
| 3-Year Avg Dividend Yield | N/A | 0.91% |
| 3-Year Total Dividends | N/A | $30.30 |
| Ex-Dividend Date | N/A | Sep 09, 2025 |